Omid Hamid
Northern Border University(SA)Cedars-Sinai Medical Center(US)International University of Africa(SD)Angeles Clinic and Research Institute(US)
Publications by Year
Research Areas
Cancer Immunotherapy and Biomarkers, Immunotherapy and Immune Responses, CAR-T cell therapy research, Melanoma and MAPK Pathways, Immune cells in cancer
Most-Cited Works
- → Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer(2012)7,940 cited
- → Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer(2015)6,153 cited
- → Pembrolizumab versus Ipilimumab in Advanced Melanoma(2015)5,779 cited
- → Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients(2014)5,215 cited
- → Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma(2013)3,383 cited
- → Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria(2009)3,202 cited